The forecasted number of confirmed Rifampicin Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in Japan shows a gradual decrease from 70 cases in 2024 to 66 cases by 2028. Compared to the 2023 data, which is yet undisclosed, these figures indicate a slight annual decline of approximately 1.43% year-on-year. Observing the five-year period from 2024 to 2028, the Compound Annual Growth Rate (CAGR) highlights an average annual reduction of around 1.45% in RR-/MDR-TB cases.

Future trends to watch for include:

Monitoring global health responses and policies that tackle drug-resistant TB to leverage successful strategies.
Advancements in medical research and treatment that could further reduce case numbers.
Potential effects of global travel and migration patterns on the spread and management of TB in Japan.